Biogen Expands Immunology Pipeline with Agreement to Acquire RayThera Inc.

Live updates

1. 5h ago

   Biogen Agrees to Acquire RayThera for Up to $1 Billion

   Biogen will acquire San Diego-based RayThera to obtain three preclinical anti-inflammatory assets. The deal is backloaded and includes a lead candidate nearing clinical development. Biogen expects to close the transaction in the third quarter of 2026.

   What's confirmed:

   • Biogen entered a definitive agreement to acquire RayThera for up to $1 billion.
   • The acquisition includes three preclinical assets with anti-inflammatory activity.
   • Biogen expects to close the transaction in the third quarter of 2026.

   Still unconfirmed:

   • The most mature asset is expected to enter Phase 1 development in Q3.
   • The deal is backloaded.
   confidence 90%
2. 3d ago

   Biogen Agrees to Acquire RayThera Inc. for Up to $1 Billion

   Biogen has entered a definitive agreement to acquire RayThera, a private San Diego biotechnology firm specializing in small molecule immunology therapies. The deal adds multiple preclinical assets to Biogen's pipeline, including a lead candidate. Biogen expects to close the transaction in the third quarter of 2026.

   What's confirmed:

   • Biogen agreed to acquire RayThera Inc. for up to $1 billion.
   • RayThera is a private biotechnology company focused on small molecule therapies in immunology.
   • The acquisition includes multiple immunology assets, including a lead asset poised for Phase 1 development.
   • Biogen expects the deal to close in the third quarter.
   • The agreement was announced on June 17, 2026.

   Still unconfirmed:

   • The deal includes three promising early-stage candidates.
   • The lead candidate is set for Phase 1 in Q3 2026.
   • The acquisition positions Biogen to enter markets in oncology.
   • Needham reiterated a Buy rating on Biogen stock following the announcement.
   confidence 95%